When to start and when to stop antifibrotic therapies

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease leading to respiratory failure and death.
• IPF has a poor prognosis, with a 5-year survival rate comparable to some cancers.
• The availability of antifibrotic drugs offers new treatment possibilities for IPF patients.

Purpose of the Study:

• To address the ongoing debate regarding the optimal timing for initiating and discontinuing antifibrotic therapy in IPF.
• To emphasize the importance of early diagnosis and treatment initiation for IPF.
• To provide guidance on when to stop antifibrotic treatment for IPF.

Main Methods:

• Review of clinical trial data, post hoc analyses, long-term safety studies, and real-life experiences with antifibrotic drugs in IPF.
• Analysis of factors influencing treatment decisions, including disease progression, prognosis, and patient/clinician awareness.
• Evaluation of evidence regarding the discontinuation of antifibrotic therapy.

Main Results:

• Despite available data, the optimal timing for starting and stopping antifibrotic treatment in IPF remains a subject of discussion.
• "Wait and watch" approaches are common, particularly in early-stage IPF, often due to lack of awareness.
• Current evidence suggests antifibrotic drugs for IPF should be continued unless significant safety concerns arise.

Conclusions:

• Treatment with antifibrotic drugs for IPF should be initiated as soon as the diagnosis is confirmed.
• Antifibrotic therapy in IPF should generally be maintained, with discontinuation primarily considered for safety reasons rather than efficacy or side effects.
• Increased awareness among patients and clinicians about IPF progression and prognosis is essential for timely and appropriate treatment management.